ProPhase Labs, Inc. (PRPH) stock

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30

$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

ProPhase Labs price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

ProPhase Labs's price to book ratio was 0.3× on Apr 30, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.1× to 2.9×, with a median of 1.6×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	0.3×	+0.1
2025	Dec 31, 2025	0.3×	−0.1
2024	Dec 31, 2024	0.4×	−1.0
2023	Dec 29, 2023	1.4×	−0.8
2022	Dec 30, 2022	2.2×	−0.1
2021	Dec 31, 2021	2.3×	−4.9
2020	Dec 31, 2020	7.2×	+5.9
2019	Jan 31, 2019	1.3×	−0.0
2018	Dec 31, 2018	1.3×	+0.6
2017	Dec 29, 2017	0.8×	+0.3
2016	Jan 29, 2016	0.5×	−0.1
2015	Dec 31, 2015	0.6×	−1.5
2014	Jan 31, 2014	2.0×	+0.5
2013	Dec 31, 2013	1.6×	–

Where these numbers come from

Parsed from the XBRL in ProPhase Labs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10.33 reverse split on Jun 1, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRPH.

Compare: PRPH vs PTCHF · PRPH vs IMNM · PRPH vs ANL · PRPH vs PTPI · PRPH vs APLM

Company	Revenue	Growth
IMNM	$4.02M	-63.3%
PRPH	$3.85M	-31.2%
PTCHF	–	–
ANL	–	–
PTPI	–	–
APLM	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 0.0%
Auditor: Fruci & Associates II, PLLC
SEC CIK: 868278

Advertisement
300 × 250

See a number that looks wrong?

ProPhase Labs price to book ratio

Price to Book Ratio at the end of each year

More ProPhase Labs figures